🔍

LUPIN - Lupin

📊 NSE: LUPIN 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/14/2025 9:20

📢 Recent Corporate Announcements

Lupin Launches Generic Xigduo XR Tablets in the United States

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 22 Apr 2026, 09:13 AM

Lupin Limited has announced the launch of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market. This product is a generic version of AstraZeneca's Xigduo XR, indicated for the treatment of type 2 diabetes. The launch follows the approval of Lupin's Abbreviated New Drug Application (ANDA) by the U.S. FDA. This expansion strengthens Lupin's existing anti-diabetic portfolio in its key U.S. market.

Launch of generic Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the U.S.
Product is bioequivalent to AstraZeneca's Xigduo XR
Available in four strengths: 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg
Strengthens Lupin's position in the U.S. anti-diabetic therapy segment

💡 Investors should monitor the ramp-up of this product as it contributes to Lupin's U.S. generic revenue stream. The successful launch of complex generics and chronic therapy products remains a key growth driver for the company.

Lupin's Somerset Facility Receives US FDA Form-483 with 3 Observations

🔵 WATCH ⭐ 7/10

REGULATORY 📅 18 Apr 2026, 11:57 AM

The U.S. FDA conducted an inspection of Lupin's manufacturing facility in Somerset, New Jersey, from April 13 to April 17, 2026. The inspection concluded with the issuance of a Form-483 containing three observations. Lupin has committed to addressing these observations and responding to the regulator within the stipulated timeframe. While the number of observations is relatively low, the company's ability to resolve them without further escalation is critical for its U.S. operations.

Inspection conducted at the Somerset, New Jersey facility from April 13 to April 17, 2026
U.S. FDA issued a Form-483 with 3 specific observations upon conclusion of the audit
Lupin is required to submit a formal response to the observations within the regulatory timeframe
The facility's compliance status is vital for maintaining current supply and future product approvals in the U.S. market

💡 Investors should monitor for the FDA's final classification of the inspection; while 3 observations are manageable, any escalation to an OAI status could impact the stock's valuation.

Lupin Incorporates Wholly Owned Subsidiary in Thailand with 3 Million Baht Capital

🟢 POSITIVE ⭐ 4/10

EXPANSION 📅 17 Apr 2026, 05:15 PM

Lupin Limited has announced the incorporation of a 100% wholly owned subsidiary in Thailand named 'Lupin (Thailand) Limited' on April 17, 2026. The subsidiary is established with a registered and paid-up capital of 3,000,000 Baht, consisting of 600,000 shares. This entity will be responsible for importing, marketing, promoting, and distributing pharmaceutical products within Thailand. The move signifies Lupin's strategic intent to strengthen its direct presence and distribution network in the Southeast Asian market.

Incorporation of 100% wholly owned subsidiary 'Lupin (Thailand) Limited' on April 17, 2026
Registered and paid-up capital of 3,000,000 Baht (approx. 68-70 Lakh INR)
Total share issuance of 600,000 shares at a par value of 5 Baht each
Business scope includes import, marketing, promotion, and distribution of pharmaceutical products
Investment made through cash consideration

💡 Investors should view this as a positive but small-scale geographic expansion. Monitor for future updates on product launches and revenue contributions from the Thai market to assess long-term growth potential in the region.

Lupin Subsidiary Settles US Antitrust Lawsuit with Humana for USD 30 Million

🟡 NEUTRAL ⭐ 6/10

LEGAL 📅 17 Apr 2026, 06:52 AM

Lupin's US subsidiary, Lupin Pharmaceuticals, Inc. (LPI), has entered into a settlement agreement with Humana Inc. to resolve civil lawsuits alleging anticompetitive behavior. Under the agreement, LPI will pay USD 30 million to settle all claims related to the 'In Re Generic Pharmaceuticals Antitrust Litigation'. Crucially, the company stated that this settlement amount has already been provided for in prior consolidated financial results, meaning no new impact on current earnings. The settlement allows Lupin to avoid the costs and uncertainties of continued litigation while maintaining its denial of any liability.

Lupin Pharmaceuticals, Inc. USA to pay USD 30 million to Humana Inc. as part of a settlement agreement.
The settlement amount was already accounted for in the company's previous consolidated financial statements.
The litigation involved allegations of federal and state antitrust law violations in the US generic market.
Agreement provides a full and final release of all claims against LPI, its parents, affiliates, and officers.
LPI continues to deny all allegations and the settlement does not imply admission of liability.

💡 Investors should view this as a positive resolution of a legal overhang, particularly as the financial impact was already provisioned. No immediate action is required as the settlement does not affect future cash flows beyond what was already anticipated.

Lupin Launches Generic Dapagliflozin Tablets (5 mg and 10 mg) in the United States

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 10 Apr 2026, 07:49 PM

Lupin Limited has announced the commercial launch of Dapagliflozin Tablets in the United States market in 5 mg and 10 mg strengths. This launch follows the U.S. FDA approval of Lupin's Abbreviated New Drug Application (ANDA), establishing the product as a bioequivalent to AstraZeneca's Farxiga®. The product targets the anti-diabetic segment, which is a core therapeutic area for Lupin. This move is expected to strengthen Lupin's generic portfolio and revenue potential in the North American market.

Launch of Dapagliflozin Tablets in 5 mg and 10 mg strengths in the US market.
Received U.S. FDA approval for ANDA as a bioequivalent to the reference brand Farxiga®.
Strengthens Lupin's position in the anti-diabetic therapy area across its 100+ global markets.
The launch leverages Lupin's extensive infrastructure of 15 manufacturing sites and 7 research centers.

💡 Investors should view this as a positive development for Lupin's US generic business. Monitor the company's upcoming quarterly results for the revenue contribution and market share gains from this specific launch.

Lupin Grants 6,495 Stock Options to Employees at ₹2 Exercise Price

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Apr 2026, 09:02 AM

Lupin Limited has announced the grant of 6,495 stock options to its employees under the Lupin Employees Stock Option Plan 2011. These options are issued at an exercise price of ₹2.00 per share, which is the face value of the stock. The vesting of these options will occur over a four-year period, with 25% vesting annually starting one year from the grant date. This is a routine corporate action aimed at employee retention and incentive alignment.

Grant of 6,495 stock options under the Lupin Employees Stock Option Plan 2011
Exercise price fixed at ₹2.00 per share, equivalent to the face value
Vesting schedule follows a 25%:25%:25%:25% pattern over four years
Each stock option entitles the holder to subscribe to one equity share of the company

💡 This is a routine disclosure with minimal impact on the company's overall equity base or financial performance. No immediate action is required from investors.

Lupin Receives U.S. FDA Approval for Generic Xigduo XR Tablets

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 08 Apr 2026, 05:20 PM

Lupin Limited has received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets. The approval covers four specific strengths: 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg. Additionally, the company received tentative approval for the 2.5 mg/1,000 mg strength. This product is a bioequivalent version of AstraZeneca's Xigduo XR, targeting the significant anti-diabetic market in the United States.

Received U.S. FDA approval for four strengths of Dapagliflozin and Metformin Hydrochloride ER Tablets
Obtained tentative approval for the 2.5 mg/1,000 mg strength of the same formulation
Product is a generic version of AstraZeneca's Xigduo XR, a major branded anti-diabetic drug
Strengthens Lupin's presence in the U.S. market for chronic therapy areas like diabetes
Lupin operates 15 manufacturing sites and 7 research centers globally to support such launches

💡 Investors should view this as a positive step in Lupin's U.S. generic strategy, likely contributing to revenue growth in the anti-diabetic segment. Monitor the commercial launch timeline and potential market share capture from the innovator.

Lupin Completes Acquisition of Netherlands-based VISUfarma B.V.

🟢 POSITIVE ⭐ 8/10

M&A 📅 01 Apr 2026, 05:24 PM

Lupin Limited, through its wholly owned subsidiary Nanomi B.V., has successfully completed the acquisition of 100% share capital of VISUfarma B.V., Netherlands. The deal, which was initially announced in September 2025, reached completion on April 1, 2026, after fulfilling all customary closing conditions. Consequently, VISUfarma and its subsidiaries have now become wholly owned step-down subsidiaries of Lupin. This acquisition is expected to bolster Lupin's footprint in the European pharmaceutical market.

Acquisition of 100% share capital of VISUfarma B.V. finalized on April 1, 2026
Transaction executed via Nanomi B.V., a wholly owned subsidiary of Lupin Limited
VISUfarma and its subsidiaries are now step-down subsidiaries of the company
Follows a series of regulatory updates starting from the definitive agreement in September 2025

💡 Investors should view this as a positive step in Lupin's international expansion strategy and monitor the subsequent impact on European revenue. No immediate action is required, but the integration of VISUfarma's portfolio will be a key metric to watch in upcoming quarterly results.

Lupin Receives Tentative U.S. FDA Approval for Sugammadex Injection

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 31 Mar 2026, 08:28 AM

Lupin Limited has received tentative approval from the U.S. FDA for its Abbreviated New Drug Application for Sugammadex Injection, available in 200 mg/2 mL and 500 mg/5 mL strengths. The product is a generic version of Merck's Bridion, used to reverse neuromuscular blockade in surgical patients aged 2 years and older. While a tentative approval indicates the product meets safety and efficacy standards, it cannot be marketed until patent or exclusivity issues are resolved. This approval strengthens Lupin's future injectable pipeline in the critical U.S. hospital segment.

Received tentative U.S. FDA approval for Sugammadex Injection (200 mg/2 mL and 500 mg/5 mL).
Product is bioequivalent to Merck’s Bridion Injection, a major brand in the neuromuscular reversal market.
Indicated for use in both adult and pediatric patients (2 years and older) undergoing surgery.
Expands Lupin's portfolio of complex generics and injectable products for the U.S. market.
Approval covers single-dose vials of 100 mg/mL concentration.

💡 Investors should monitor for the transition from tentative to final approval, which will depend on the expiration of innovator patents. This development is a positive indicator of Lupin's R&D capabilities in the complex injectable space.

Lupin Increases Stake in Philippines Subsidiary MPPI to 56.28% via Buyback

🟢 POSITIVE ⭐ 6/10

M&A 📅 30 Mar 2026, 09:40 AM

Lupin Limited's indirect subsidiary, Multicare Pharmaceuticals Philippines, Inc. (MPPI), has completed a buyback of 2,813,811 equity shares from existing shareholders. Lupin's intermediate holding company, Nanomi B.V., did not participate in the buyback, resulting in its stake in MPPI increasing from 51% to 56.28%. MPPI is a profitable entity with a FY25 turnover of PHP 2,096.6 million. This consolidation of ownership was funded through MPPI's retained earnings, requiring no cash outflow from Lupin.

Indirect shareholding in MPPI increased from 51% to 56.28% effective March 30, 2026.
MPPI bought back 2,813,811 equity shares using its own retained earnings.
MPPI reported a turnover of PHP 2,096.6 million and Net Worth of PHP 1,265.5 million for FY25.
The transaction results in higher earnings consolidation for Lupin without any fresh capital investment.

💡 Investors should view this as a positive structural move that increases Lupin's exposure to the Philippines market without capital expenditure. No immediate action is required, but it strengthens the company's long-term consolidated bottom line.

Lupin Announces Trading Window Closure from April 1, 2026, for Q4 and FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 25 Mar 2026, 03:52 PM

Lupin Limited has informed the exchanges that its trading window for dealing in company securities will be closed starting April 1, 2026. This closure is a mandatory regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the announcement of audited financial results for the quarter and financial year ending March 31, 2026. The window will remain closed until 48 hours after the results are declared. The specific date for the board meeting to approve these results will be announced in due course.

Trading window closure effective from April 1, 2026, for all Designated Persons.
Closure pertains to the audited financial results for the quarter and year ending March 31, 2026.
The window will reopen 48 hours after the official declaration of the financial results.
Compliance is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

💡 This is a routine regulatory filing with no direct impact on stock valuation; investors should await the announcement of the board meeting date for Q4 FY26 results.

Lupin Receives U.S. FDA Tentative Approval for Pitolisant Tablets (Generic Wakix)

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 25 Mar 2026, 09:16 AM

Lupin Limited has secured tentative approval from the U.S. FDA for its Pitolisant Tablets in 4.45mg and 17.8mg strengths. This product is a generic version of Wakix, which is indicated for the treatment of narcolepsy. The tablets will be manufactured at Lupin's Nagpur facility in India. While the approval is tentative, it marks a significant step in expanding Lupin's CNS portfolio in the U.S. market.

Received tentative U.S. FDA approval for Pitolisant Tablets (4.45mg and 17.8mg)
Product is bioequivalent to the reference brand drug Wakix®
Manufacturing will be localized at the company's Nagpur facility in India
Strengthens Lupin's presence in the U.S. Central Nervous System (CNS) therapy segment

💡 Investors should view this as a positive development for Lupin's medium-term U.S. pipeline, though they should wait for clarity on the final approval and launch timeline. Monitor the stock for potential gains as the company moves closer to commercializing this narcolepsy treatment.

Lupin Allots 135,892 Equity Shares Under Employee Stock Option Plan

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Mar 2026, 12:42 PM

Lupin Limited has allotted 135,892 fully paid-up equity shares of ₹2 each to employees who exercised their vested stock options. This allotment was approved by the company's Operations and Finance Committee on March 24, 2026. As a result, the total paid-up share capital of the company has increased to ₹91,43,58,222. This is a routine corporate action that leads to a very marginal dilution of the existing equity base.

Allotment of 135,892 equity shares of face value ₹2 each under ESOP schemes.
Total paid-up share capital increased to ₹91,43,58,222.
Total number of equity shares outstanding now stands at 45,71,79,111.
The shares were issued to employees of the company and its subsidiaries upon exercise of vested options.

💡 This is a routine administrative update with negligible impact on share value. Investors should continue to monitor the company's core pharmaceutical operations and regulatory filings.

Lupin Subsidiary LMS Expands Dabhasa Facility to Boost Peptide and CRDMO Capabilities

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 19 Mar 2026, 08:15 AM

Lupin Manufacturing Solutions (LMS), a wholly-owned subsidiary of Lupin, has announced a strategic expansion of its Dabhasa facility in India to scale its peptide building-blocks platform. The expansion includes a new block for CRDMO services and two specialized units dedicated to peptide manufacturing. This move targets the high-growth market for complex therapeutics, including peptides and Antibody-Drug Conjugates (ADCs). By strengthening its infrastructure, Lupin aims to capture a larger share of the global advanced pharmaceutical solutions market through its team of over 250 scientists.

Strategic expansion of Dabhasa facility to scale peptide building-blocks and CRDMO capabilities.
Addition of a new CRDMO block and two specialized units for dedicated peptide manufacturing.
Focus on complex modalities including protected amino acids, peptides, and biologic ADCs.
LMS leverages a team of over 250 scientists to support early development to commercial scale.
Strengthens Lupin's position in the global peptide ecosystem and complex therapeutics market.

💡 Investors should view this as a positive long-term move to diversify into high-margin CDMO and complex generic segments. Monitor the revenue contribution from the LMS subsidiary in upcoming quarters to gauge the execution and scaling of this expansion.

Lupin and Zydus Sign Licensing Deal to Co-market Semaglutide Injection in India

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 17 Mar 2026, 12:05 PM

Lupin Limited has entered into a licensing and supply agreement with Zydus Lifesciences to co-market Semaglutide Injection (15 mg/3 ml) in the Indian market. Under the agreement, Lupin will market the product under the brands Semanext and Livarise, while Zydus will continue with its own brands. Lupin is required to pay Zydus upfront licensing fees and milestone-based payments for these semi-exclusive rights. This partnership targets the high-growth segments of Type 2 diabetes and chronic weight management in India.

Lupin gains semi-exclusive rights to co-market Zydus's innovative Semaglutide Injection (15 mg/3 ml) in India.
Lupin will market the therapy under brand names Semanext and Livarise using a reusable pen device.
The agreement involves Lupin paying Zydus upfront licensing fees and milestone payments.
Therapy targets Type 2 diabetes and obesity management for adults with BMI of 30 kg/m2 or greater.
The partnership leverages Lupin's extensive domestic reach to expand access to GLP-1 therapies.

💡 Investors should view this as a strategic positive as it strengthens Lupin's cardio-metabolic portfolio with a high-demand GLP-1 therapy. Monitor the market share gains and the impact of milestone payments on Lupin's margins in the coming quarters.

View All LUPIN Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Formulations segment accounted for 92.6% of consolidated revenues in 9M FY2024, while the API segment contributed 6.0%. The API business grew 3% YoY to INR 1,177.2 Cr in FY2025. Consolidated revenue grew 13.5% YoY in FY2025 to INR 22,707.9 Cr and 24% YoY in Q2 FY2026 to INR 7,048 Cr.

Geographic Revenue Split

In FY2025, North America contributed 38% (up 16% YoY), India 34% (INR 7,577.3 Cr, up 14% YoY), EMEA 11% (up 22% YoY), Growth Markets 9% (up 7% YoY), and API business 5%.

Profitability Margins

Operating profit margin (OPM) improved to 18.6% in 9M FY2024 from 10.8% in FY2023. Profit Before Tax (PBT) increased by 65.8% in FY2025. Return on Capital Employed (ROCE) reached 25% by the end of Q2 FY2026, up from 21.6% in FY2025.

EBITDA Margin

EBITDA margin for Q2 FY2026 was approximately 24-25%. Consolidated EBITDA rose 39.4% YoY in FY2025, driven by operating leverage and improved product mix.

Capital Expenditure

Regular capital expenditure is estimated at INR 700-800 Cr per annum, primarily funded through internal accruals.

Credit Rating & Borrowing

Short-term rating reaffirmed at [ICRA]A1+ for INR 3,000 Cr facilities. The company maintains a strong liquidity position with cash and bank balances of INR 5,397.8 Cr as of March 31, 2025.

⚙️ Operational Drivers

Raw Materials

Key raw materials include anti-TB APIs and high-potency APIs. Captive API consumption accounts for 75-80% of total requirements, reducing external dependency.

Key Suppliers

Not disclosed in available documents; however, the company is actively working on alternate vendor development to manage gross margins.

Capacity Expansion

Capex of INR 700-800 Cr per annum is planned for maintenance and incremental expansion. Higher capacity utilization at key manufacturing sites has improved operating leverage.

Raw Material Costs

Raw material costs are managed through high captive integration (75-80%). Gross margins improved in FY2025 due to a shift toward complex generics and respiratory products.

Manufacturing Efficiency

Operating leverage improved due to higher capacity utilization and digitization of commercial operations, contributing to a 25% ROCE in Q2 FY2026.

Logistics & Distribution

Distribution costs are optimized through supply chain agility and digitization, though specific INR values were not disclosed.

📈 Strategic Growth

Expected Growth Rate

24%

Growth Strategy

Growth will be driven by a differentiated pipeline in complex generics (inhalations and injectables), biosimilars (Ranibizumab, Pegfilgrastim), and expansion into underpenetrated European markets like Italy and Spain through a EUR 190 million acquisition. India growth is focused on chronic therapies and new verticals like diagnostics.

Products & Services

Anti-TB medicines, anti-diabetes formulations, respiratory inhalers, complex injectables, biosimilars, and diagnostic services.

Brand Portfolio

Lupin, Lupin Manufacturing Solutions (LMS), Enzene (Biosimilars).

New Products/Services

New product launches in the US and India, including biosimilars like Ranibizumab and Pegfilgrastim, are expected to drive significant margin expansion.

Market Expansion

Expansion into Italy and Spain via the acquisition of Nanomi B.V. for EUR 190 million, expected to be completed by December 2025.

Market Share & Ranking

8th largest company in the Indian Pharmaceutical Market (3.4% share) and 3rd largest pharmaceutical player in the US by prescriptions.

Strategic Alliances

Lupin Manufacturing Solutions (LMS) is positioned as a differentiated CDMO partner for global pharma innovators.

🌍 External Factors

Industry Trends

The industry is shifting toward complex generics and CDMO outsourcing due to 10-15% annual price erosion in commoditized generics. Lupin is positioning itself through high-barrier respiratory products and biosimilars.

Competitive Landscape

Intense competition in US generics and biosimilars, with some players exiting due to pricing pressures, allowing Lupin to gain market share in niche segments.

Competitive Moat

Lupin holds a durable moat as the only WHO pre-qualified company globally for both anti-TB APIs and formulations, alongside a dominant 42% US revenue share from complex inhalations.

Macro Economic Sensitivity

Vulnerable to US healthcare reforms, changes in the US tariff regime, and domestic pricing controls under the National List of Essential Medicines (NLEM).

Consumer Behavior

Increased demand for chronic therapies and diagnostic services in India is driving a 14% growth in the domestic formulation business.

Geopolitical Risks

Trade barriers and regulatory shifts in the US and EU could impact the 49% of revenue derived from these regulated markets.

⚖️ Regulatory & Governance

Industry Regulations

Subject to USFDA manufacturing standards (warning letters pending for Tarapur and Mandideep) and NLEM pricing controls in India.

Environmental Compliance

The company received an ESG rating from NSE Sustainability Ratings & Analytics Limited in December 2025.

Taxation Policy Impact

Financial statements are prepared in accordance with Indian Accounting Standards (Ind AS).

Legal Contingencies

Ongoing investigation by the US DoJ anti-trust division regarding price fixing and collusion allegations; impact remains an event risk.

⚠️ Risk Analysis

Key Uncertainties

Adverse outcomes from US DoJ investigations or failure to resolve USFDA warning letters could impact revenue by restricting market access or incurring heavy fines.